These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 37046312)

  • 1. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
    Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
    J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.
    Sun R; Sun Y; Wu C; Liu Y; Zhou M; Dong Y; Du G; Luo H; Shi B; Jiang H; Li Z
    Mol Ther; 2023 Nov; 31(11):3193-3209. PubMed ID: 37735875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
    Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
    PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.
    Sun R; Luo H; Su J; Di S; Zhou M; Shi B; Sun Y; Du G; Zhang H; Jiang H; Li Z
    Mol Ther; 2021 Jan; 29(1):60-74. PubMed ID: 33010818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
    Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
    Front Immunol; 2022; 13():863346. PubMed ID: 35874730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
    Dai Z; Lin X; Wang X; Zou X; Yan Y; Wang R; Chen Y; Tasiheng Y; Ma M; Wang X; Cheng H; Yu X; Liu C
    Cancer Immunol Immunother; 2024 Mar; 73(4):61. PubMed ID: 38430267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
    McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma.
    Dorst DN; Smeets EMM; Klein C; Frielink C; Geijs D; Trajkovic-Arsic M; Cheung PFY; Stommel MWJ; Gotthardt M; Siveke JT; Aarntzen EHJG; van Lith SAM
    Mol Pharm; 2023 Aug; 20(8):4319-4330. PubMed ID: 37485886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
    Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
    Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment.
    Lin Y; Li B; Yang X; Cai Q; Liu W; Tian M; Luo H; Yin W; Song Y; Shi Y; He R
    Neoplasia; 2019 Dec; 21(12):1133-1142. PubMed ID: 31759251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma.
    Kawase T; Yasui Y; Nishina S; Hara Y; Yanatori I; Tomiyama Y; Nakashima Y; Yoshida K; Kishi F; Nakamura M; Hino K
    BMC Gastroenterol; 2015 Sep; 15():109. PubMed ID: 26330349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity.
    Akai M; Noma K; Kato T; Nishimura S; Matsumoto H; Kawasaki K; Kunitomo T; Kobayashi T; Nishiwaki N; Kashima H; Kikuchi S; Ohara T; Tazawa H; Choyke PL; Kobayashi H; Fujiwara T
    Br J Cancer; 2024 Jun; 130(10):1647-1658. PubMed ID: 38555315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
    Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
    Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
    Das S; Valton J; Duchateau P; Poirot L
    Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
    Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
    Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy.
    Shahvali S; Rahiman N; Jaafari MR; Arabi L
    Drug Deliv Transl Res; 2023 Jul; 13(7):2041-2056. PubMed ID: 36840906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.